Preface |
|
xix | |
|
|
xxi | |
|
Acquired immunodeficiency syndrome (AIDS) and fatigue |
|
|
1 | (1) |
|
|
1 | (1) |
|
Adrenocorticotropin hormone (ACTH) |
|
|
1 | (1) |
|
|
1 | (1) |
|
|
1 | (1) |
|
|
2 | (1) |
|
|
2 | (1) |
|
Antidiuretic hormone (ADH)/Arginine vasopressin |
|
|
2 | (1) |
|
|
3 | (1) |
|
|
3 | (1) |
|
|
4 | (1) |
|
|
4 | (1) |
|
|
4 | (1) |
|
|
4 | (1) |
|
|
4 | (1) |
|
|
5 | (3) |
|
|
8 | (1) |
|
|
8 | (1) |
|
Borna disease virus (BDV) |
|
|
8 | (1) |
|
|
9 | (1) |
|
Brain positron emission tomography (PET) |
|
|
9 | (1) |
|
Branched-chain amino acids (BCAA) |
|
|
9 | (1) |
|
|
9 | (1) |
|
Cardiovascular deconditioning |
|
|
10 | (1) |
|
|
11 | (1) |
|
|
11 | (1) |
|
Chronic fatigue syndrome (CFS), definition |
|
|
11 | (4) |
|
|
15 | (1) |
|
|
15 | (1) |
|
Circulating immune complexes |
|
|
16 | (1) |
|
Cognitive behavioral therapy |
|
|
16 | (1) |
|
|
16 | (1) |
|
|
17 | (1) |
|
Connective tissue and rheumatologic disorders |
|
|
17 | (1) |
|
|
17 | (1) |
|
|
18 | (1) |
|
|
18 | (1) |
|
Corticotropin-releasing hormone (CRH) |
|
|
18 | (1) |
|
|
18 | (1) |
|
|
18 | (1) |
|
|
18 | (1) |
|
|
18 | (1) |
|
|
18 | (1) |
|
|
19 | (1) |
|
|
19 | (1) |
|
|
19 | (1) |
|
|
20 | (1) |
|
|
21 | (1) |
|
|
21 | (1) |
|
|
21 | (1) |
|
|
21 | (1) |
|
|
21 | (1) |
|
|
22 | (1) |
|
|
22 | (1) |
|
|
22 | (1) |
|
|
22 | (1) |
|
|
23 | (1) |
|
|
24 | (1) |
|
|
24 | (1) |
|
Familial chronic fatigue syndrome |
|
|
25 | (1) |
|
|
26 | (1) |
|
|
26 | (1) |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
27 | (1) |
|
Gastrointestinal pathology |
|
|
27 | (1) |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
29 | (1) |
|
|
29 | (1) |
|
|
30 | (1) |
|
|
30 | (1) |
|
|
30 | (2) |
|
|
32 | (1) |
|
|
32 | (1) |
|
|
32 | (1) |
|
Human herpesvirus-6 (HHV-6) |
|
|
32 | (1) |
|
Human herpesvirus-7 (HHV-7) |
|
|
32 | (1) |
|
|
32 | (1) |
|
|
32 | (1) |
|
Hypothalamus-pituitary-adrenal (HPA) axis |
|
|
33 | (1) |
|
|
33 | (1) |
|
|
33 | (1) |
|
|
33 | (3) |
|
Immune cell phenotypic distributions |
|
|
36 | (1) |
|
|
36 | (1) |
|
Inflammatory bowel disease |
|
|
37 | (1) |
|
|
37 | (1) |
|
|
37 | (1) |
|
|
37 | (1) |
|
Insulin-like growth factors (IGFs) |
|
|
37 | (1) |
|
|
37 | (1) |
|
Interleukin-1 (IL-1) and soluble IL-1 receptors |
|
|
38 | (3) |
|
Interleukin-2 (IL-2) and soluble IL-2 receptor |
|
|
41 | (1) |
|
|
41 | (1) |
|
Interleukin-6 (IL-6) and soluble IL-6 receptor |
|
|
42 | (1) |
|
|
42 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
Juvenile onset chronic fatigue syndrome |
|
|
43 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
Low cysteine-glutathione syndrome |
|
|
44 | (1) |
|
|
44 | (1) |
|
|
44 | (3) |
|
|
47 | (1) |
|
Magnetic resonance imaging (MRI) |
|
|
47 | (1) |
|
|
47 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
Monoamine oxidase (MAO) inhibitors |
|
|
48 | (1) |
|
|
48 | (1) |
|
|
49 | (1) |
|
Multiple chemical sensitivity (MCS) syndrome |
|
|
49 | (2) |
|
|
51 | (1) |
|
|
52 | (1) |
|
|
52 | (2) |
|
Myalgic encephalomyelitis |
|
|
54 | (1) |
|
|
54 | (1) |
|
|
54 | (1) |
|
Natural killer (NK) cells |
|
|
55 | (2) |
|
|
57 | (1) |
|
Neurally mediated hypotension |
|
|
58 | (1) |
|
|
58 | (1) |
|
|
58 | (4) |
|
|
62 | (1) |
|
|
62 | (1) |
|
|
63 | (1) |
|
|
63 | (2) |
|
|
65 | (1) |
|
|
65 | (1) |
|
|
65 | (1) |
|
|
65 | (3) |
|
|
68 | (1) |
|
|
68 | (1) |
|
|
68 | (1) |
|
|
68 | (1) |
|
|
69 | (1) |
|
|
69 | (1) |
|
Pediatric chronic fatigue syndrome |
|
|
69 | (1) |
|
|
70 | (1) |
|
|
71 | (1) |
|
Phosphorus magnetic resonance spectroscopy |
|
|
71 | (1) |
|
|
71 | (1) |
|
|
71 | (1) |
|
|
71 | (1) |
|
Polycystic ovarian syndrome |
|
|
71 | (1) |
|
|
71 | (1) |
|
|
72 | (1) |
|
Post-Lyme disease syndrome (PLS) |
|
|
72 | (1) |
|
|
72 | (1) |
|
Post--Q-fever fatigue syndrome |
|
|
72 | (1) |
|
Postural tachycardia syndrome |
|
|
72 | (1) |
|
|
72 | (1) |
|
|
72 | (1) |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
74 | (1) |
|
|
75 | (1) |
|
|
76 | (1) |
|
|
77 | (1) |
|
|
77 | (1) |
|
|
77 | (1) |
|
Red blood cell distribution width |
|
|
77 | (1) |
|
|
77 | (1) |
|
Regulation of respiration |
|
|
77 | (1) |
|
|
77 | (1) |
|
|
78 | (1) |
|
Reticular activating system |
|
|
78 | (1) |
|
|
78 | (1) |
|
|
78 | (1) |
|
|
78 | (1) |
|
|
78 | (1) |
|
|
78 | (1) |
|
Seasonal affective disorder |
|
|
79 | (1) |
|
Selective serotonin reuptake inhibitors (SSRIs) |
|
|
79 | (1) |
|
|
79 | (1) |
|
|
80 | (1) |
|
|
80 | (1) |
|
Sick building syndrome (SBS) |
|
|
80 | (1) |
|
|
80 | (2) |
|
|
82 | (1) |
|
|
82 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
|
83 | (1) |
|
Sub-anaerobic threshold exercise test |
|
|
84 | (1) |
|
Sympathetic hypersensitivity |
|
|
84 | (1) |
|
Systemic lupus erythematosus (SLE) |
|
|
84 | (1) |
|
|
84 | (1) |
|
Temporomandibular disorders |
|
|
84 | (1) |
|
|
84 | (1) |
|
|
84 | (1) |
|
|
85 | (1) |
|
|
85 | (1) |
|
Tumor growth factor-beta (TGF-beta) |
|
|
85 | (1) |
|
Tumor necrosis factors (TNFs) and soluble TNF receptors |
|
|
85 | (1) |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
87 | (1) |
|
|
87 | (2) |
Notes |
|
89 | (66) |
Index |
|
155 | |